02.24.15
Bedford, Mass.-based N2 Biomedical LLC has received a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Dental & Craniofacial Research (NIDCR), to investigate a new antimicrobial biodegradable bone graft material. The project will be carried out in collaboration with Huinan Liu, Ph.D., at the University of California at Riverside.
“Prevention of implant-related infections after surgical repair of traumatic craniofacial injuries is an important goal,” according to Arash Aslani, principal investigator. “Current materials utilized to address large bone defects, such as polymethyl methacrylate (PMMA) beads, are not ideal because they do not degrade and thus require multiple surgeries; they are also prone to infection despite the addition of antibiotics. The objective of this Phase I study is to develop a new biodegradable metallic material coupled with an innovative coating system that provides longer-term antibiotic delivery to the local environment. This technology has the potential for significantly reducing infection rates and obviating the need for a subsequent surgical procedure to remove the beads.”
“We are pleased with the receipt of this grant from NIH,” said Mark Little, president and CEO of N2 Biomedical. “The project has the potential for addressing an important clinical problem by improving the management of bone fractures and reducing the occurrence of infection. As a provider of coating and surface treatment services for medical devices, this technology will complement our existing commercial processes for orthopedic materials and devices. The grant will also allow us to work with and further develop technologies for the next generation of advanced biodegradable metallic materials.”
N2 Biomedical provides surface modification services for improving the performance of medical devices.
“Prevention of implant-related infections after surgical repair of traumatic craniofacial injuries is an important goal,” according to Arash Aslani, principal investigator. “Current materials utilized to address large bone defects, such as polymethyl methacrylate (PMMA) beads, are not ideal because they do not degrade and thus require multiple surgeries; they are also prone to infection despite the addition of antibiotics. The objective of this Phase I study is to develop a new biodegradable metallic material coupled with an innovative coating system that provides longer-term antibiotic delivery to the local environment. This technology has the potential for significantly reducing infection rates and obviating the need for a subsequent surgical procedure to remove the beads.”
“We are pleased with the receipt of this grant from NIH,” said Mark Little, president and CEO of N2 Biomedical. “The project has the potential for addressing an important clinical problem by improving the management of bone fractures and reducing the occurrence of infection. As a provider of coating and surface treatment services for medical devices, this technology will complement our existing commercial processes for orthopedic materials and devices. The grant will also allow us to work with and further develop technologies for the next generation of advanced biodegradable metallic materials.”
N2 Biomedical provides surface modification services for improving the performance of medical devices.